Загрузка...
ATRT-11. MARKED RESPONSE TO ATEZOLIZUMAB IN A PATIENT WITH RHABDOID TUMOR: A CASE STUDY FROM THE IMATRIX-ATEZOLIZUMAB TRIAL
BACKGROUND: Rhabdoid tumors (RTs) are aggressive, rare tumors usually diagnosed in early childhood. They portend poor prognosis, despite multi-modality treatment. Atezolizumab targets programmed death-ligand 1 (PD-L1), leading to enhanced anti-cancer T-cell activity. The iMATRIX-Atezolizumab study (...
Сохранить в:
| Опубликовано в: : | Neuro Oncol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5474990/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.010 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|